• The company’s FASForm(TM) technology produces materials already used across multiple existing segments. 
• What differentiates Frontieras within these sectors is the breadth of outputs generated from a single feedstock.
• Frontieras broke ground last month on its first commercial-scale project, which is designed to process approximately 7,500 tons of coal per day.

For decades, coal’s critics and coal’s defenders have been arguing about the same thing: whether to burn it. Frontieras North America Inc. has a different question entirely. What happens when the industry stops burning coal and starts fractionating it?

The answer, according to the company’s FASForm(TM) technology, is six commercial product streams — diesel, naphtha, jet fuel, hydrogen, purified industrial carbon and ammonium sulfate fertilizer — all produced from a single feedstock, through a closed-loop process, with no combustion and no waste. The markets those products serve carry a combined estimated value exceeding $2.1 trillion. That’s what coal actually is, when the world stops asking it to be something it was never designed to be.

Clearly, the scale of the opportunity targeted by Frontieras is significant.      Rather than relying on emerging or speculative demand categories, the company’s product portfolio aligns with markets that already support large-scale global trade, mature supply chains and benchmark commodity pricing structures. These include transportation fuels, hydrogen, petrochemical feedstocks, industrial carbon products and agricultural inputs that are deeply integrated into the global economy.

Crucially, Frontieras does not depend on creating new categories of consumption or introducing entirely new infrastructure systems. Instead, the company’s FASForm process produces materials already used across transportation, aviation, agriculture, steelmaking, refining and industrial manufacturing. Diesel remains one of the world’s main transportation fuels, powering freight movement, construction equipment and industrial machinery. Jet fuel demand continues to rise alongside global aviation activity, while hydrogen plays a critical role in refining, chemical production and industrial processing.

The company’s inclusion of naphtha within its product slate also aligns Frontieras with one of the core feedstocks used in global petrochemical manufacturing. Naphtha is widely used in the production of plastics, synthetic fibers, industrial solvents and chemical intermediates that support countless downstream industries. At the same time, Frontieras’s FASCarbon(TM) product positions the company within technical carbon and coke markets tied to steel manufacturing, industrial heating and materials production.

Agricultural markets further expand the company’s market potential. The ammonia and sulfur compounds generated during the FASForm process can be repurposed into fertilizer products, including ammonium sulfate and sulfuric acid. Fertilizers remain essential to global food production systems, with demand supported by population growth and agricultural intensity worldwide. Industry estimates place the global fertilizers market at roughly $230 billion in 2025, reflecting continued demand tied to agriculture, crop yields and global food production.

What differentiates Frontieras within these sectors is the breadth of outputs generated from a single feedstock. The company’s FASForm process fractionates coal into multiple commercial products simultaneously rather than using coal for a single end purpose. The process produces approximately 2.3 barrels of liquid fuels from each ton of coal processed while also generating hydrogen and purified technical carbon products. This approach allows one facility to participate across several large industrial markets at the same time.

The company’s first commercial-scale project in Mason County, West Virginia, demonstrates the scale at which Frontieras intends to operate. Frontieras recently broke ground on the facility, which is designed to process approximately 7,500 tons of coal per day, or roughly 2.7 million tons annually. According to the company, this volume represents approximately 0.5% of current annual U.S. coal production, a scale designed to remain aligned with existing market demand, transportation infrastructure and logistics systems.

This incremental scaling strategy is an important component of the company’s market positioning. Rather than overwhelming existing commodity markets with oversized production capacity, Frontieras has structured its facility design around integration with established industrial demand profiles. Existing transportation networks, refining systems, industrial buyers and commodity trading structures already support the products the company plans to produce. 

The Mason County facility also reflects the company’s focus on infrastructure compatibility. Frontieras has stated that the plant will use existing coal supply chains while producing fuels, hydrogen and industrial materials. The company has already secured buyers for portions of the output. The company’s long-term feedstock and offtake arrangements reinforce its strategy of operating within established industrial ecosystems rather than building entirely new ones.

Frontieras’ products serve several of the world’s most essential industries. Diesel and jet fuel support transportation, freight and aviation, while hydrogen is widely used in refining and industrial manufacturing. Technical carbon and coke products remain important for steel production and industrial heating, and fertilizer products help support global agriculture and food production. Demand across these sectors continues to grow alongside infrastructure development, manufacturing activity and population growth worldwide.

Coal itself also remains one of the world’s most abundant energy resources. According to the U.S. Energy Information Administration, global proved recoverable coal reserves total approximately 1.16 trillion short tons. Frontieras’ model is built on increasing the economic value extracted from that resource by converting it into multiple industrial outputs rather than limiting it to a single-use fuel source.

As Frontieras North America advances its first commercial deployment, the company is positioning itself at the intersection of established industrial demand and abundant domestic feedstock supply. By aligning its product portfolio with trillion-dollar global markets supported by existing infrastructure, mature supply chains and long-standing industrial applications, Frontieras is building a scalable model centered on coal’s value as a diversified industrial resource rather than a single-purpose commodity.

For more information about Frontieras, visit the company’s website at www.Frontieras.com.

NOTE TO INVESTORS: The latest news and updates relating to Frontieras are available in the company’s newsroom at https://ibn.fm/Frontieras

• Approximately 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, yet no approved off-the-shelf solution capable of regenerating hyaline-like cartilage is currently available in the U.S. market
• Regentis’ GelrinC(R) is a cell-free hydrogel implant designed to repair focal knee cartilage defects in a single approximately 10-minute procedure, with CE Mark approval in Europe and a pivotal U.S. FDA trial now more than 50% enrolled
• A newly patented solvent-free manufacturing process that increases GelrinC(R) production yield by 400% signals Regentis’ preparation for commercial scale-up as clinical and regulatory milestones approach

Knee cartilage damage remains one of the most stubborn problems in orthopedic medicine. Unlike many other tissues in the body, articular cartilage has little natural ability to heal because it lacks both direct blood supply and the biological machinery required for meaningful regeneration. For decades, treatment options have reflected that limitation. Microfracture, the long-standing standard of care, attempts to stimulate repair by drilling into the underlying bone in an attempt to mimic a repair trigger. It can provide short-term symptom relief, but long-term cartilage durability remains a recognized challenge with standard treatment. More advanced cell-based therapies exist, but they introduce substantial complexity, cost, manufacturing requirements, and long procedural delays that limit broader adoption. Despite roughly 472,500 arthroscopic knee procedures in the U.S. each year involving knee cartilage damage, the market still lacks an approved, ready-to-use truly regenerative solution capable of combining procedural simplicity with sustained long-term outcomes. Regentis is positioning durability as a central differentiator, with clinical data demonstrating sustained outcomes over extended follow-up periods.

Regentis Biomaterials (NYSE American: RGNT) is targeting that gap with GelrinC(R), its lead regenerative cartilage repair platform designed as a cell-free alternative to conventional treatment pathways.

The Limitations of Today’s Standard

For active patients with focal cartilage damage, current treatment options often involve trade-offs.

Microfracture remains widely used because it is relatively straightforward and familiar to orthopedic surgeons, but the tissue it produces is fibrocartilage rather than true hyaline cartilage, making durability a persistent concern. Cell-based procedures offer a more biologically sophisticated approach, but typically require an initial biopsy, weeks of laboratory cell expansion, and a second surgical procedure for implantation. Costs for those approaches can range from approximately $38,000 to $45,000 per case.

Other repair methods may involve harvesting plugs from healthy bone and cartilage and requiring two surgeries, introducing additional trauma through surgical complexity and donor-site concerns. No currently available cartilage repair solution combines off-the-shelf availability, a single short procedure, regenerative cartilage restoration, and long-term durability in a single treatment approach.

A Different Regenerative Model

GelrinC(R) represents a fundamentally different regenerative approach designed to simplify one of orthopedics’ most complex treatment categories.

The product is an acellular hydrogel composed of polyethylene glycol and denatured fibrinogen, delivered into a cartilage defect in liquid form and then cured into a solid degradable hydrogel implant using ultraviolet light. The implant is designed to gradually resorb in a synchronized manner as native surrounding cells migrate inward, supporting regeneration of hyaline-like cartilage tissue over time.

From a practical standpoint, the workflow is materially simpler than cell-based alternatives. The procedure takes approximately 10 minutes, can be performed using open or minimally invasive techniques, and does not require tissue harvesting, cell culturing, or delayed reimplantation. Surgeons use the product at the point of care rather than coordinating a multi-step treatment pathway.

That combination of procedural simplicity and regenerative intent is central to the company’s commercial thesis.

Clinical Progress and Commercial Preparation

Clinical data have provided the early foundation for that thesis.

In a Phase II study involving 56 patients across Northern Europe and Israel, GelrinC(R) demonstrated statistically significant improvement in its primary endpoint measuring KOOS outcomes at 24 months. GelrinC(R) treatment resulted in 100% greater overall KOOS (Knee Injury and Osteoarthritis Outcome Score) clinical outcomes compared to microfracture controls, including significant improvements in pain, function, and patient recovery measures, compared to microfracture controls.  In parallel, quantitative MOCART imaging scores – a validated, FDA-accepted MRI assessment method – suggested near-complete structural repair and among the highest reported cartilage repair outcomes in the field. No serious adverse events were reported.

Those results supported CE Mark marketing approval in Europe, where Regentis is now actively building a commercialization infrastructure and physician adoption pathways ahead of planned market entry. 

In April, the company announced a collaboration with Humanitas Research Hospital in Milan, one of Europe’s leading orthopedic and sports medicine centers, alongside internationally recognized cartilage regeneration expert Prof. Elizaveta Kon. The initiative is part of Regentis’ broader strategy to establish a European Centers of Excellence network designed to support surgeon education, clinical guidance, and large-scale physician adoption ahead of commercialization.

Commercial readiness is also showing up operationally. In March, Regentis announced a newly developed solvent-free manufacturing process that more than quadruples GelrinC(R) production yield per batch. Beyond improving production economics, the manufacturing advancement suggests active preparation for broader commercial deployment.

The U.S. Regulatory Path

In the United States, GelrinC(R) is advancing through a pivotal FDA study under an Investigational Device Exemption pathway.

The study uses a single-arm design with historical microfracture controls previously accepted by regulators, rather than a concurrent randomized comparator arm. Enrollment is targeted at 80 patients, with more than half already recruited and treated according to company disclosures.

If enrollment proceeds as expected, the program could move toward PMA submission in late 2027.

Orthopedic innovation often moves slowly, particularly in categories where legacy procedures remain entrenched despite well-understood limitations. Knee cartilage repair appears to be one of those markets. Regentis is pursuing an opportunity built around procedural simplicity, regenerative intent, and commercial practicality in a category where those elements have rarely aligned in a single product.

For more information, visit the company’s website at www.Regentis.co.il.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• Nevada Organic Phosphate Inc. is positioning its Murdock Project in Nevada to supply organic rock phosphate fertilizer to the growing North American organic agriculture sector.
• Global fertilizer supply chains are under renewed pressure as conflict-linked shipping disruptions through the Strait of Hormuz affect phosphate and nitrogen markets.
• Although Morocco controls the largest phosphate reserves, China remains the world’s largest phosphate fertilizer producer and exporter,  underscoring geopolitical concentration risk in global supply.
• Nevada Organic Phosphate’s business model centers on direct application raw phosphate, requiring limited processing beyond grinding and bagging.
• The company is targeting the expanding U.S. organic food market, estimated at roughly US$35 billion annually.
• Rising fertilizer and transportation costs are increasingly linked to broader food inflation trends affecting North American consumers.

As geopolitical instability places renewed pressure on global fertilizer markets, smaller North American phosphate projects are attracting increased investor attention. Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, is focused on its Murdock Project in Elko County, Nevada, offering a potentially large scale domestic supply of raw organic phosphate fertilizer for U.S. agriculture, perfect for the certification requirements of the growing organic food market. 

The company is rare in avoiding the chemical processing used with most fertilizers. The project is designed around a comparatively simple operating model: mine phosphate-bearing material, grind it, bag it and ship it directly to agricultural customers. American farming environmental practices are rapidly moving to a direct application of REACTIVE rather than soluble chemical phosphate. NOP does not have to compete with the conventional chemical agricultural input industry.

That proposition comes at a time when fertilizer security has become a growing concern for governments as well as farmers and investors. Global fertilizer markets have been rattled in recent months by disruptions linked to the conflict involving Iran and shipping restrictions through the Strait of Hormuz. Around 30% of global fertilizer trade normally moves through the narrow maritime corridor (https://ibn.fm/cDypH).

The consequences are already affecting agricultural supply chains. Nitrogen and phosphate shipments have faced delays, while fertilizer costs and freight rates have climbed. China, the world’s largest producer of nitrogen and phosphate fertilizers, has prioritized domestic supply, limiting export availability at a time of heightened global demand.

The tightening market has broader implications beyond agriculture. U.S. consumers are already seeing elevated food prices linked partly to higher transportation and agricultural input costs. A separate report noted that Americans could face additional upward pressure on food prices if fertilizer shortages persist into future planting seasons (https://ibn.fm/atwyR).

Against that backdrop, domestic phosphate supply has become strategically relevant. Phosphorus is a critical nutrient for plant growth and is used primarily in agriculture through phosphate fertilizers. Roughly 90% of global phosphorus consumption is tied to agricultural applications. While Morocco controls the world’s largest phosphate reserves, China remains the dominant producer and exporter of processed phosphate fertilizers, creating concentration risk within global supply chains.

Nevada Organic Phosphate is attempting to position itself as a U.S.-based alternative focused specifically on organic and regenerative agriculture markets. The company says the Murdock Project hosts an Exploration Target Mineral Inventory, or ETMI, estimated at between 10 million and 46 million tonnes of phosphate-bearing material grading between 3% and 15% P2O5. The estimate is based on an average thickness of 3.5 metres and a specific gravity of 2.61.

In addition to the primary Murdock target zone, Nevada Organic Phosphate has identified three additional target areas, which the company says could increase total ETMI potential to between 200 million and 220 million tonnes.

The fact that Nevada Organic Phosphate is targeting direct application reactive phosphate for organic farming systems matters because conventional phosphate fertilizer production often requires extensive chemical processing, including acid treatment and large industrial facilities. By contrast, direct application phosphate involves applying finely ground phosphate rock directly to soils, particularly in regenerative and organic agricultural systems where biological soil activity helps release nutrients over time. The company argues this approach could lower capital expenditure requirements while reducing environmental impact. Nevada Organic Phosphate says the material would not require major downstream chemical processing and would avoid contamination risks associated with some conventional fertilizer production methods.

Management also points to broader trends in U.S. agriculture that increasingly favor regenerative farming practices and organic certification standards. Organic food demand in North America has expanded steadily over the past decade, driven by both consumer preference and retailer adoption. That growth has created parallel demand for organic agricultural inputs, including phosphate products approved for organic farming applications.

Nevada’s location could also provide logistical advantages. The Murdock Project sits within trucking and rail distance of major U.S. agricultural markets, potentially reducing transport dependence compared with imported phosphate products arriving through international shipping routes. The project’s positioning also aligns with evolving U.S. critical minerals policy. Phosphate has increasingly been recognized as strategically important because of its role in food production and agricultural security.

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

• The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to reach more than $10 billion by 2031.
• Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs.
• The most significant development to date came when Oncotelic announced the successful integration of approximately 28 million scientific abstracts, into its PDAOAI platform.

Artificial intelligence is no longer a buzzword in the life sciences; rather, it is rapidly becoming the defining infrastructure layer of modern drug development. The companies that control the most intelligent platforms may ultimately control the industry’s future. Among the clinical-stage players quietly positioning themselves at the center of this shift is Oncotelic Therapeutics (OTCQB: OTLC), a California-based oncology company that has spent years building a proprietary AI platform and is now turning that platform into something more ambitious than a drug-discovery tool.

The broader market context makes Oncotelic’s strategy worth taking seriously. The global AI in drug-discovery market was valued at approximately $3.25 billion in 2026 and is projected to grow at a compound annual growth rate of roughly 26% through 2031, reaching over $10 billion. Oncology, notably, is the leading therapeutic segment within that market, accounting for the largest revenue share among all disease areas as of 2025.

This puts Oncotelic at the intersection of two powerful forces: the explosive commercial potential of AI-driven platforms and the urgent, ongoing need for better cancer therapies. The question investors and industry observers are beginning to ask is not whether AI belongs in drug development — that debate is settled — but rather whether a lean, clinical-stage biotech can build a platform sophisticated enough to compete with, and license to, the giants of the pharmaceutical world.

The case that small players can out-innovate big pharma is not merely theoretical. As of early 2026, more than 270 pharmaceutical and biotechnology companies globally have active AI drug discovery programs, up from fewer than 80 in 2020. Meanwhile, the volume of partnering deals between AI platform companies and large pharma has increased by more than 340% over that same five-year period. 

The acceleration reflects a structural reality: Large pharmaceutical companies are buyers and partners as much as they are builders, and startups and clinical-stage biotechs with validated, proprietary platforms have an opening to define themselves as indispensable infrastructure providers.

Oncotelic’s central technology, the PDAOAI platform, was designed from the outset to be something more than a research accelerator for internal programs. The platform embeds, clusters and queries large biomedical datasets to surface citation-backed, testable hypotheses, without training bespoke large language models on proprietary data, a distinction that carries meaningful regulatory and intellectual property implications. 

In late 2025, Oncotelic opened public access to PDAOAI through a dedicated Discord research channel, publishing a curated TGF-β literature corpus of more than 125,000 PubMed abstracts, a move that simultaneously demonstrated scientific transparency and showcased the platform’s capacity to organize and interrogate the scientific literature at scale. The company’s TGF-β2 program, advanced through its lead candidate OT-101, has been a cornerstone of Oncotelic’s clinical pipeline for years, but PDAOAI now gives that work a technological backbone that could make the platform itself as valuable as any single drug candidate.

The most significant development to date came in late April 2026, when Oncotelic announced the successful integration of approximately 28 million scientific abstracts, described by the company as representing the totality of scientific knowledge, into its PDAOAI platform. This integration was not merely a data ingestion exercise. The milestone enabled real-time application of that knowledge base within a jointly developed robotics platform built in partnership with TechForce Robotics Inc., allowing scientific knowledge to be directly embedded into automated workflows operating in regulated pharmaceutical environments. The combined platform is designed to improve operational efficiency, reduce reliance on manual processes, and support compliance across pharmaceutical development and manufacturing, capabilities that speak directly to some of the most stubborn cost and risk challenges in drug manufacturing today.

The pattern that emerges from Oncotelic’s recent trajectory is one of a company that has systematically converted scientific and technical development into a commercial platform without losing sight of its clinical mission. AI in biotech is entering a phase where success will be defined less by novel algorithms and more by whether organizations can move from experimentation to dependable infrastructure, systems that are interpretable to scientists and defensible to regulators. 

With 28 million abstracts powering its robotics platform, a GMP-compliant deployment partnership in place and an oncology pipeline actively generating clinical data, Oncotelic appears to be doing exactly that. For investors and industry watchers asking whether a small clinical-stage player can out-innovate big pharma, Oncotelic Therapeutics is building its answer one integration milestone at a time.

Public-market examples such as Sangamo Therapeutics, Inc. (OTCQB: SGMO), CytoDyn Inc. (OTCQB: CYDY), Netlist, Inc. (OTCQB: NLST), and NorthWest Biotherapeutics, Inc. (OTCQB: NWBO) demonstrate continued investor appetite for platform-driven companies built around proprietary technology ecosystems, infrastructure-layer intellectual property, and long-duration scientific optionality beyond any single product candidate.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, continues to bolster its foundations amid surging demand for silver
• With its 100%-owned Clayton Silver Project, the company is looking to unlock its largely untapped potential, ultimately stamping its position as an integral player in the global silver production market
• In May 2026, the company announced that it’s making good progress on a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000, with proceeds going into a geophysical survey and an initial diamond-drilling program
• CMX is positioning itself to take advantage of the high if volatile price of silver, currently over 50% higher than November 2025 and more than 3X a few years ago

CMX (CSE: CXC) (OTC: CXXMF), an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, continues to bolster its foundations amid ongoing geopolitical developments and a surging demand for silver. With the previous metal currently serving as a very accessible investment, especially compared to the price of gold, CMX sees a massive opportunity both for growth, and for stamping its position as a leader in its space.

Where many struggle with the production of this precious metal, CMX has a significant upper hand with its 100% owned Clayton Silver Project located in the Bayhorse Mining District in central Idaho. With a history dating back to the late 1800s, this mine shows historical recorded ore productions of approximately USD $660,000,000. With 31 patented claims and 20 unpatented claims spanning 1,028 acres, the property still has vast untapped potential and unlocking it would make CMX an integral player in the global silver production market (https://ibn.fm/aFnj5).

So far, the Clayton project has only been partially explored. As a response to that, the company is moving forward with exploration, working off geological findings that suggest a growing probability of undiscovered cracks in the overall deposit, which suggest multiple silver veins in the property. The findings thus far have given the company’s management all the validation they need to double down on the property and seek funding for the exploration of the mine.

CMX is hard at work to complete the announced non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000. Once closed, the gross proceeds would be geared toward geophysical surveys and an initial diamond-drilling program on the property, a major step toward bringing the mine to life (https://ibn.fm/ZDrus).

Finally, it’s important to note that the demand for silver continues to grow as supply continues to be under pressure, and that such things as private transactions between companies and miners do not show up in price listings or demand statistics. 

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

• MindBio Therapeutics is expanding its AI voice analytics platform to include fatigue detection alongside drug and alcohol impairment screening.
• MindBio filed a patent application covering detection of neurologically active substances and fatigue through voice analysis.
• Fatigue prediction module will be added to Edge AI Intoxication Detection Kiosks targeted at industrial workplaces.
• Management says commercial testing of kiosk hardware and software remains on track for late Q2 2026.
• The company is positioning its technology as a non-invasive alternative to breath, saliva, blood and laboratory-based testing systems, with mining, aviation, transportation and construction among the initial sectors targeted for deployment.

MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, is broadening the scope of its platform with the development of a fatigue prediction model designed for high-risk workplace environments. The company announced May 11 that it has developed a fatigue recognition system using speech analytics and proprietary artificial intelligence models, according to a news release (https://ibn.fm/4KNzG).

The fatigue detection capability is expected to become an additional feature within MindBio’s planned Edge AI Intoxication Detection Kiosks, which are being designed to identify signs of alcohol, drug impairment and fatigue from short voice samples.

Management says the system is intended for deployment in industries where alertness and operational safety are closely monitored, including mining, aviation, transportation and construction.

The announcement reflects a broader strategy by MindBio to position voice analytics as a scalable alternative to conventional impairment screening methods such as breathalyzers, saliva tests, urine analysis and laboratory-based toxicology testing. Rather than relying on physical samples, the company’s platform analyzes speech characteristics captured through a microphone and processes the audio using machine learning models trained on large voice datasets.

MindBio says its existing prediction platform has been developed using more than 50 million data points and evaluates more than 140 acoustic markers associated with intoxication and neurological impairment.

The newly announced fatigue detection module expands the company’s commercial focus beyond alcohol and drug screening into a broader workplace monitoring category that includes alertness and cognitive readiness.

In its recent patent application, titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics,” the company outlined claims related to identifying fatigue and impairment from voice analysis using short spoken phrases or pangrams. Management described the filing as part of a broader intellectual property strategy around AI-powered diagnostics and speech-based health analysis.

Chief Executive Officer Justin Hanka said the company sees an opportunity to expand into the digital health diagnostics market through non-invasive detection systems that can operate in real-time workplace environments.

“The digital health diagnostics market represents a significant opportunity for MindBio to leverage its non-invasive diagnostics technology with a first mover advantage in the detection of neurologically active substances and now fatigue from voice and AI,” Hanka said. “The company has claimed 15 world firsts in its recent patent application filing and is progressing towards commercialisation with the development of its Edge AI Intoxication & Fatigue Detection Kiosks.”

The company has stated that commercial testing of its Edge AI kiosk hardware and software remains on schedule for late Q2 2026.

MindBio’s initial commercial emphasis has centered on mining operations, particularly in South America, where employers face strict workplace safety requirements and large operational workforces. Mining sites often require routine alcohol and drug screening because impairment-related incidents can create operational shutdowns, financial losses and worker safety risks. Traditional testing methods can also create logistical bottlenecks in remote industrial settings where thousands of workers may need to be screened regularly.

MindBio’s proposed system is designed to allow workers to provide a brief voice sample at an entry-point kiosk, with the AI model then generating an immediate assessment based on detected speech patterns.

The company argues that voice-based testing may offer a more scalable approach for organizations seeking frequent or high-volume screening without relying exclusively on laboratory infrastructure or invasive testing procedures.

Fatigue monitoring may also represent a significant adjacent opportunity for industrial operators. In sectors such as aviation, trucking and mining, fatigue-related incidents remain a major workplace safety concern, particularly in environments involving long shifts, remote operations or continuous production schedules.

The broader workplace testing market has continued to expand as employers increase investment in safety compliance and operational risk management. MindBio is entering a market that includes traditional testing equipment manufacturers, laboratory service providers and emerging AI-based diagnostic companies. Its differentiation strategy centers on speed, portability and non-invasive analysis delivered through voice recognition technology.

Beyond mining, the company has identified additional potential applications across aviation, law enforcement, construction, transportation and call centers, where large-scale screening can be difficult or expensive using traditional methods. Management has also discussed the possibility of broader health and wellness applications tied to speech analytics, although the company’s near-term commercial priorities remain focused on intoxication and fatigue detection.

For more information, visit the company’s website at www.MindBioTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• SPARC AI is developing software designed to help drones operate in GPS-denied and electronically contested environments
• The company’s Overwatch platform focuses on autonomous navigation and precision targeting without requiring additional hardware
• Growing global investment in electronic warfare, autonomous defense systems, and counterspace resilience is accelerating demand for software-defined military capability

With modern warfare rapidly evolving, the competitive advantage is shifting from hardware to software systems that enable autonomy, precision, and resilience in contested environments. SPARC AI (CSE: SPAI) (OTCQB: SPAIF) is strategically positioning itself for this transformation through its Overwatch platform, a software-only solution designed to provide GPS-denied navigation and precision targeting for drones and autonomous systems operating on electronically degraded battlefields (https://nnw.fm/ojiGt) (ibn.fm/51tMh).

The urgency around these capabilities has become increasingly visible, especially through the Ukrainian war, where mass-produced drones have altered the economics of conflict. Reports show that Ukraine currently produces millions of drones each year, underscoring how scalable unmanned systems are becoming and how integral they are to modern military operations. Yet the conflict has exposed a major weakness: many drones remain very dependent on GPS signals and continuous human control, leaving them vulnerable to spoofing, jamming, and electronic warfare attacks.

This vulnerability is fueling a shift across global defense programs. NATO, the Pentagon, and allied governments are increasingly prioritizing electronic warfare resilience, autonomy, and software-defined battlefield systems. Analysts have noted that control of the electromagnetic spectrum is quickly becoming one of the defining factors in modern warfare, as militaries seek ways to blind drones, disrupt communications, and degrade satellite-dependent targeting systems (https://nnw.fm/Jn3fh) (ibn.fm/0v529).

SPARC AI’s Overwatch platform directly addresses these emerging issues. Instead of relying solely on expensive hardware modifications, the company’s software is designed to operate with existing cameras and onboard flight systems, potentially enabling quick deployment across large fleets of cheaper drones. This software-focused architecture could preserve scalability and affordability, which makes mass drone deployment attractive in the first instance (https://nnw.fm/AbB9H) (ibn.fm/4F5UP).

The rising importance of software-enabled warfare extends beyond just drones. Recent analysis of the war in Ukraine has underscored how GPS infrastructure, satellite communications, and space-enabled intelligence systems have become foundational to modern battlefield coordination. Also, electronic warfare and cyberattacks targeting those systems are becoming more common (ibn.fm/s6MI3).

The ability to navigate, identify targets, and maintain operational continuity without depending on vulnerable satellite infrastructure is emerging as a vital defense priority.

SPARC AI appears to be aligning its technology roadmap with this broader shift toward resilient autonomous operations. According to the company, Overwatch has already entered operational field testing and deployment agreements in Ukraine, where persistent electronic warfare conditions provide a demanding real-world validation environment. The company has made inroads on the international stage through licensing agreements and defense-related partnerships in regions such as India and the Middle East.

Industrywide momentum continues building around autonomous defense technologies. Companies across sectors are advancing autonomous maritime systems, AI-driven drones, and scalable unmanned platforms for increasingly contested operational environments. However, as drone hardware becomes more commoditized, the intelligence layer that enables autonomous decision-making, navigation, and targeting may ultimately become the more valuable differentiator.

SPARC AI is strategically placing itself in the industry. By focusing on software-defined autonomy rather than hardware manufacturing, the company aims to provide a scalable intelligence layer capable of supporting broader autonomous defense applications across air, land, and maritime domains.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• Forward Industries recently announced both financial and operational results for Q2 2026, a quarter which it said was defined by disciplined execution across the business.
• The Q2 highlights for Forward included appointing a new CFO, executing a share repurchase, securing a $40 million institutional debt facility, completing a minority investment in OnRe, and implementing a cost reduction plan.
• Forward Industries also gave a treasury update, announcing that liquid SOL holdings as of March 31, 2026, were over 7 million, and that Forward’s validator infrastructure generated between 6.5% and 7.2% gross annual percentage yield (“APY”).
• Q2 revenue reached $13 million, more than 4X higher than the prior year period.

Forward Industries (NASDAQ: FWDI), a Solana treasury company, recently announced financial and operating results for fiscal Q2 2026, which ended March 31, 2026 (https://ibn.fm/Gii28). According to the Chairman of Forward Industries, Kyle Samani, the second fiscal quarter for Forward was “defined by disciplined execution across the business — sharpening our cost structure, strengthening our balance sheet, and deepening our engagement within the Solana ecosystem.”

Forward outlined many highlights from Q2 in the release and conference call about the results, including the appointment of Mark Brazier as CFO, who brings more than 25 years of traditional finance and digital assets experience to the team.

Forward completed a strategic share repurchase that saw it taking back over 6 million shares of its common stock from an institutional investor, at an aggregate purchase price of around $27.4 million, reducing Forward’s basic shares outstanding by 7.4%.

The repurchase was financed through a $40 million institutional debt facility it secured with Galaxy Digital, which has a weighted average maturity of 5 months and a weighted average interest rate of around 3.4%. The loan not only helped Forward fund the repurchase, but also provides access to capital to fund future growth and support capital allocation initiatives.

Forward also completed a minority investment in OnRe, a regulated onchain reinsurance company, and implemented a cost reduction plan to materially improve its cost structure.

On the financial side, Forward announced that revenue for Q2 reached $13 million, which is more than 4 times higher than the $3.1 million of the previous year. In addition, Q2 2026 General, and Administrative Expenses (“SG&A”) came to $6.6 million, which is less than the $7.2 million of the prior quarter, reflecting the initial execution against the cost reduction plan it announced. The company also had around $16.6 million in cash as of March 31, 2026, and has an annualized SOL/sh growth around 44%.

Finally, Forward provided an update on its SOL treasury strategy. It has liquid SOL holdings of just over 7 million SOL. Since inception, Forward’s validator infrastructure has generated between 6.5% and 7.2% gross annual percentage yield (“APY”) before fees, which outperforms other top peer validators. Also, around 25% of Forward’s SOL holdings are represented as fwdSOL, which is its proprietary liquid staking token that enables the company to earn native staking yield while maintaining liquidity, and serves as collateral supporting the $40 million facility from Galaxy Digital.

In the conference call about the Q2 results, leadership at Forward also spoke about the growth of the Solana Network, highlighting the $1.1 trillion in network activity, the more than 3 million daily active users, 11,000 active developers, and an 8X payments volume growth year-over-year.

About Forward Industries Inc. (NASDAQ: FWDI)

Forward Industries is managing and building a large-scale Solana (SOL) treasury backed by some of the most influential investors in the digital asset space. To create long-term shareholder value, Forward not only accumulating SOL, but also actively participates in the Solana ecosystem by strategically deploying assets through on-chain activities like staking, lending, and participating in decentralized finance (“DeFi”).

For more information, visit the Forward Industries website at www.ForwardIndustries.com.

NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) and may include paid advertising.

• LaFleur Minerals is announcing the strategic appointment of senior executives with decades of industry experience to help lead the company as it moves toward gold production at its Swanson Gold Deposit and Beacon Gold Mill in the Abitibi Greenstone Belt
• The first stage of this strategy is the addition of Marc Ducharme as Vice President of Exploration who will help bolster the company’s exploration and operational efficiency and strategic plan to acquire additional high caliber mining projects in the region and generate confidence with stockholders
• LaFleur’s assets include the Beacon Gold Mill, Swanson Gold Project and McKenzie East Gold Project, all part of its mine-to-market near-term gold production operation on 450 exploration mining claims the company owns in the Abitibi
• LaFleur expects to reap the benefits of gold prices, a rail transport line crossing its properties, and worker resources in nearby Val-d’Or, Québec

Near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) has introduced new expertise to its management team amid the company’s preparations to begin operations at its Beacon Gold Mill, nearby Swanson Gold Project, and the newly acquired McKenzie East Gold Project.

The appointment of Marc Ducharme as Vice President of Exploration “materially strengthens LaFleur Minerals’ technical and operational capabilities at a critical inflection point, directly enhancing both execution certainty and corporate value,” according to a news release issued by the company May 5 (https://ibn.fm/Hb4Zs).

Mr. Ducharme’s expertise spans the full mining lifecycle, from discovery through production including recently with Probe Gold reducing technical and operational risk, strengthening capital markets credibility, and positioning LaFleur Minerals to accelerate near-term production, generate cash flow, acquire additional advanced mining projects, and deliver sustainable growth in shareholder value.

Mr. Ducharme’s resume includes more than 35 years of experience in geological exploration across mining jurisdictions that include Ontario’s and Québec’s prolific Abitibi region. He will not only help advance the company’s in-progress advanced exploration program in the region, but also will help identify and evaluate additional acquisition targets for the company near the Beacon Gold Mill.

The company is also seeking additional high-caliber executives to complement its existing executive and technical team to quickly advance its projects and grow LaFleur Minerals into a mid-tier gold producer.

The company’s statement also notes an increase of stock option offerings to company management and consultants, as well as a new marketing contractor.

LaFleur Minerals has made strategic acquisitions of property and facilities during the last few years near Val d’Or, Quebec — an established base for labor and resources that serve as the underpinnings of mineral exploration activities in the Abitibi.

The Beacon mill and Swanson site are the company’s flagship gold production resources within the more than 450 exploration mining claims it owns, situated on about 55,350 acres (nearly 22,400 hectares) in the Eastern Canadian region.

The Beacon Gold Mill is a previously operating facility undergoing some upgrades with expectations of resuming operation this quarter. It will initially process material at 750 tonnes per day (“TPD”) but LaFleur anticipates building to 1,250 TPD by the end of the first year of operation. 

Material from Swanson will provide the initial feedstock, and the McKenzie East Gold Project is expected to complement Swanson as a value-accretive addition while drilling continues assessing gold resources at both sites.

Recent drilling at Swanson has allowed LaFleur to expand the limits of its current resource model and establish the potential of finding a large-scale gold system on the property. Drill results include findings of wide mineralization in two zones, with 1.18 g/t Au over 255.04 meters and 1.65 g/t Au over 136.01 meters.

Operators also found higher grades at 2.29 g/t Au over 68.30 meters at a third drill location.

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

Disseminated on behalf of Planet Ventures Inc. (CSE: PXI) (OTC: PNXPF) and may include paid advertising.

• Planet Ventures holds multiple private space investments spanning launch systems, satellite software, orbital energy infrastructure, microgravity robotics, and cislunar development
• CEO Etienne Moshevich has outlined a 2026 mandate to expand the portfolio while continuing to build management and advisory capabilities
• The company has grown its cash and asset base from approximately $5 million to roughly $20 million over the past two and a half years, providing capacity for additional deployment

The most compelling opportunities in transformative industries often emerge long before public market investors have access. By the time companies in sectors such as artificial intelligence, biotechnology, or aerospace reach major exchanges, much of the earliest value creation has already accrued to venture capital firms, institutional investors, and strategic backers. The rapidly expanding space economy is following a similar pattern, raising a practical question for retail investors: how to gain exposure before the largest liquidity events occur.

Planet Ventures (CSE: PXI) (OTC: PNXPF) is positioning itself as one possible answer. Structured as a publicly traded investment issuer, the company provides investors with exposure to private space and aerospace companies that would otherwise remain inaccessible to most retail participants. Rather than building a single operating business within the sector, Planet is assembling a diversified portfolio across multiple layers of the emerging space economy.

A Public Vehicle for Private Market Exposure

The company’s investment structure is central to the thesis.

In a recent TechMediaWire podcast interview, Chief Executive Officer Etienne Moshevich described Planet’s evolution over the past two and a half years, explaining how the company transformed from approximately $5 million in cash and assets into a platform now holding roughly $20 million while shifting toward a dedicated space-focused investment strategy.

His broader argument was straightforward: by the time retail investors gain access to many marquee private aerospace names through public listings, much of the steepest growth curve may already be behind them. Planet’s structure is designed to bridge that gap by offering public market investors indirect access to earlier-stage private opportunities.

That model resembles venture capital portfolio construction more than traditional public equity investing. The objective is not that every investment becomes a category leader. Rather, diversification across multiple emerging platforms creates exposure to outsized winners that can define portfolio performance.

Layers of the Space Economy

Planet’s current portfolio spans over distinct segments of the broader space economy.

Antaris Inc. represents the software layer, developing cloud-based mission design and satellite operations platforms intended to streamline spacecraft deployment and management. The company closed a $28 million Series A round in 2026 led by WestWave Capital with participation from Lockheed Martin Ventures.

Mantis Space addresses orbital infrastructure through power distribution systems designed to support satellites and future in-space operations requiring persistent energy availability.

General Astronautics brings exposure to autonomous robotics in microgravity environments, targeting scientific research, manufacturing, and laboratory operations where human astronaut time remains exceptionally expensive.

Galactic Resource Utilization Space, or GRU Space, extends the portfolio into cislunar infrastructure and habitation technologies, reflecting longer-duration exposure to lunar development concepts.

Taken together, the portfolio reflects a deliberate effort to diversify not simply across companies, but across functional layers of the broader space economy.

The 2026 Expansion Plan

Management is not positioning the current portfolio as the finished product.

Moshevich stated during the podcast that Planet’s 2026 objective is to expand with more investments while continuing to strengthen the internal team responsible for sourcing, evaluating, and managing future opportunities.

That buildout already includes strategic advisor Tansu Yegen, whose background spans senior leadership roles at Apple, Microsoft, IBM Global Business Services, Samsung Mobile, and other global technology platforms. Additional management and advisory appointments are expected as the platform expands.

The stated strategy is disciplined growth rather than concentration risk.

In venture-style investing, outcomes tend to follow power-law mathematics, where a small number of outsized winners often drive the majority of returns. Expanding a portfolio improves exposure to those asymmetric outcomes while reducing reliance on any single technical thesis or private company execution path.

Why Timing Matters

The macro backdrop is becoming increasingly relevant.

The World Economic Forum has projected the global space economy could approach $1.8 trillion by 2035, driven by growth across communications, defense, infrastructure, manufacturing, logistics, and lunar development. At the same time, sovereign investment in space capabilities is accelerating, including Canada’s growing role through Artemis participation, lunar infrastructure commitments, and broader aerospace development initiatives.

That does not eliminate risk. Private investing remains speculative by nature, particularly in frontier sectors where timelines can slip and technologies may fail to commercialize.

But Planet’s proposition is not based on certainty. It is based on access.

For public investors seeking exposure to earlier-stage space opportunities rather than waiting for mature public listings, Planet Ventures is building a structure designed to participate in that phase of value creation.

For more information, visit www.PlanetVenturesInc.com.

NOTE TO INVESTORS: The latest news and updates relating to PNXPF are available in the company’s newsroom at https://ibn.fm/PNXPF

Disclaimer

Investor Brand Network (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Planet Ventures Inc. will make aggregate payments of $100,000  to us to provide marketing services for a term of 1 year. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. 

Forward-Looking Statements

This document contains forward-looking statements within the meaning of applicable securities legislation. Such statements include, without limitation, statements regarding: Planet Ventures’ investment strategy and objectives; anticipated developments in the commercial space industry, including the growth of orbital energy and space robotics markets; the projected growth of the global space economy; Planet Ventures’ expectations regarding the strategic importance of its investments in Mantis Space and General Astronautics; the anticipated role of orbital energy technologies and robotic servicing systems in future in-orbit operations; and the potential for these technologies to become foundational to the next generation of commercial space activity.

Forward-looking statements are not guarantees of future performance. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof and Planet Ventures undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Risk Factors

Investing in Planet Ventures and its portfolio companies involves a high degree of risk. The following is a summary of key risk factors. This is not an exhaustive list, and additional risks may exist that are not currently known:

• Early-Stage Investment Risk. Portfolio companies have limited operating histories and are pre-revenue. Investments are speculative and may result in a total loss of capital.
• Technology Risk. The orbital energy and lunar habitation technologies underlying the Company’s investments are unproven at commercial scale and may not be successfully developed or deployed.
• Regulatory Risk. Space sector operations require licenses and approvals from domestic and international regulatory bodies. Failure to obtain or maintain these could materially delay or prevent operations.
• Market Risk. Commercial demand for in-space power systems and lunar services has not been established at scale. Projected market growth may not be realized within anticipated timeframes.
• Liquidity Risk. Investments in private, early-stage companies are illiquid. There is no guarantee of a market for these securities or the ability to exit on favorable terms.
• Capital Risk. Portfolio companies may require additional funding that may not be available, or may be available only on dilutive or restrictive terms.
• Macroeconomic and Geopolitical Risk. Adverse macroeconomic conditions or geopolitical developments could disrupt the Company’s investment strategy or the operations of portfolio companies.
• Key Personnel Risk. The Company’s performance depends in part on retaining key personnel and advisors. Loss of key individuals could adversely affect the Company’s operations and investment activities